Show simple item record

dc.contributor.authorGhidini, Men_US
dc.contributor.authorTomasello, Gen_US
dc.contributor.authorBotticelli, Aen_US
dc.contributor.authorBarni, Sen_US
dc.contributor.authorZabbialini, Gen_US
dc.contributor.authorSeghezzi, Sen_US
dc.contributor.authorPassalacqua, Ren_US
dc.contributor.authorBraconi, Cen_US
dc.contributor.authorPetrelli, Fen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-16T09:29:25Z
dc.date.issued2017-09en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28684194en_US
dc.identifierS1365-182X(17)30804-3en_US
dc.identifier.citationHPB (Oxford), 2017, 19 (9), pp. 741 - 748en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1149
dc.identifier.eissn1477-2574en_US
dc.identifier.doi10.1016/j.hpb.2017.05.010en_US
dc.description.abstractINTRODUCTION: The use of adjuvant treatment (AT) in resected biliary tract cancers (BTC) is still controversial. No efficacy comparison has been performed between chemotherapy (CT) and chemoradiotherapy (CTRT). A systematic review of the available evidence regarding adjuvant chemotherapy (AC) in resected BTC was performed. METHODS: PubMed, EMBASE, Web of Science, SCOPUS and The Cochrane Library databases were searched for relevant articles published. Only studies including at least 50 patients affected by tumors of gallbladder, intrahepatic, perihilar, and distal bile ducts were considered. Data were pooled using a random-effects model. The primary endpoint of the study was overall survival (OS). RESULTS: Thirty studies were analyzed with a total of 22,499 patients, 3967 of whom received AC. Eleven cohorts included Western patients and 19 were Asiatic. Surgeries were classified as R0 with negative margins, R1 with positive microscopic and R2 with positive macroscopic margins. Weighted mean OS difference among experimental (AC) and control arm was 4.3 months (95% CI 0.88-7.79, P = 0.014). AC reduced the risk of death by 41% (Hazard ratio [HR] = 0.59, 95% CI 0.49-0.71; P < 0.001). CONCLUSIONS: AC administration gives an OS benefit in resected BTC. The results of prospective randomized studies are awaited in order to define the standard AT in BTC.en_US
dc.format.extent741 - 748en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectBiliary Tract Neoplasmsen_US
dc.subjectBiliary Tract Surgical Proceduresen_US
dc.subjectChemotherapy, Adjuvanten_US
dc.subjectChi-Square Distributionen_US
dc.subjectHumansen_US
dc.subjectRisk Factorsen_US
dc.subjectSurvival Analysisen_US
dc.subjectTime Factorsen_US
dc.subjectTreatment Outcomeen_US
dc.titleAdjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-05-20en_US
rioxxterms.versionofrecord10.1016/j.hpb.2017.05.010en_US
rioxxterms.licenseref.startdate2017-09en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfHPB (Oxford)en_US
pubs.issue9en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume19en_US
pubs.embargo.termsNot knownen_US
icr.researchteamSignal Transduction & Molecular Pharmacologyen_US
dc.contributor.icrauthorBraconi, Chiaraen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record